Lundbeck controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2013
Citalopram generic-delay agreements
The European Commission fined Lundbeck €93.8 million after finding that agreements with generic-drug manufacturers delayed the entry of less expensive citalopram products. The Commission also fined several generic manufacturers.
2011
Nembutal and execution-use controversy
Lundbeck faced criticism because its pentobarbital product Nembutal was used in executions in the United States. The company adopted a specialty-pharmacy distribution program intended to prevent sales to prisons in states carrying out lethal-injection executions, then transferred the portfolio to Akorn under a continuing restriction arrangement.